Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients.
Nannan WuJia DaiMingquan GuoJianhui LiXin ZhouFeng LiYuan GaoHongping QuHongzhou LuJing JinTao LiLei ShiQingguo WuRuoming TanMingli ZhuLan YangYun LingShunpeng XingJianzhong ZhangBangxin YaoShuai LeJingmin GuJinghong QinJie LiMengjun ChengDemeng TanLinlin LiYiyuan ZhangZhaoqin ZhuJinfeng CaiZhigang SongXiaokui GuoLi-Kuang ChenTong-Yu ZhuPublished in: Emerging microbes & infections (2021)
Phage therapy is recognized as a promising alternative to antibiotics in treating pulmonary bacterial infections, however, its use has not been reported for treating secondary bacterial infections during virus pandemics such as coronavirus disease 2019 (COVID-19). We enrolled 4 patients hospitalized with critical COVID-19 and pulmonary carbapenem-resistant Acinetobacter baumannii (CRAB) infections to compassionate phage therapy (at 2 successive doses of 109 plaque-forming unit phages). All patients in our COVID-19-specific intensive care unit (ICU) with CRAB positive in bronchoalveolar lavage fluid or sputum samples were eligible for study inclusion if antibiotic treatment failed to eradicate their CRAB infections. While phage susceptibility testing revealed an identical profile of CRAB strains from these patients, treatment with a pre-optimized 2-phage cocktail was associated with reduced CRAB burdens. Our results suggest the potential of phages on rapid responses to secondary CRAB outbreak in COVID-19 patients.
Keyphrases
- coronavirus disease
- pseudomonas aeruginosa
- acinetobacter baumannii
- sars cov
- intensive care unit
- end stage renal disease
- newly diagnosed
- ejection fraction
- multidrug resistant
- drug resistant
- prognostic factors
- pulmonary hypertension
- peritoneal dialysis
- escherichia coli
- stem cells
- risk assessment
- patient reported outcomes
- coronary artery disease
- mechanical ventilation
- mycobacterium tuberculosis
- bone marrow
- human health